Strategies for the management of postoperative atrial fibrillation

Orthopedics

Volumn 34, Issue 5, 2011, Pages

  Bekker, Jennifer G ^a   Macaulay, Tracy E ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTICOAGULANT AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DABIGATRAN; DIGOXIN; DILTIAZEM; DOFETILIDE; DRONEDARONE; ESMOLOL; FLECAINIDE; IBUTILIDE; METOPROLOL; PAROXYPROPIONE; PLACEBO; PROCAINAMIDE; PROPAFENONE; SOTALOL; VERAPAMIL; WARFARIN; ANTIARRHYTHMIC AGENT;

CARDIOVERSION; CEREBROVASCULAR ACCIDENT; CHRONIC DRUG ADMINISTRATION; COMBINATION CHEMOTHERAPY; COST OF ILLNESS; DISEASE CONTROL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG SELECTIVITY; HEART ATRIUM FIBRILLATION; HEART HEMODYNAMICS; HEART RATE VARIABILITY; HEART RHYTHM; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART SURGERY; HOSPITAL COST; HUMAN; HYPOTENSION; LENGTH OF STAY; LOADING DRUG DOSE; MONOTHERAPY; PATIENT SELECTION; POSTOPERATIVE COMPLICATION; REVIEW; RISK REDUCTION; SINUS RHYTHM; THROMBOEMBOLISM; THROMBOSIS PREVENTION; TORSADE DES POINTES; UNSPECIFIED SIDE EFFECT; ARTICLE; ORTHOPEDIC SURGERY;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; HUMANS; ORTHOPEDIC PROCEDURES; POSTOPERATIVE COMPLICATIONS;

EID: 79955884152     PISSN: 01477447     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Maisel WH, Rawn JD, Stevenson WG. Atrial fibrillation after cardiac surgery. Ann Intern Med. 2001; 135(12):1061-1073. (Pubitemid 33151027)
2. Polanczyk CA, Goldman L, Marcantonio ER, Orav EJ, Lee TH. Supraventricular arrhythmia in patients having noncardiac surgery: clinical correlates and effect on length of stay. Ann Intern Med. 1998; 129(4):279-285. (Pubitemid 28394572)
3. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002; 347(23):1825-1833. doi: 10.1056/NEJMoa021328 (Pubitemid 35417773)
4. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002; 347(23):1834-1840. doi: 10.1056/NEJMoa021375 (Pubitemid 35417774)
5. Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008; 358(25):2667-2677. doi: 10.1056/NEJMoa0708789 (Pubitemid 351860859)
6. Carlsson J, Miketic S, Windeler J, et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol. 2003; 41(10):1690-1696. doi: 10.1016/S0735-1097 (03)00332-2
7. Opolski G, Torbicki A, Kosior DA, et al. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. Chest. 2004; 126(2):476-486. doi: 10.1378/chest.126.2.476 (Pubitemid 39093433)
8. Wann LS, Curtis AB, January CT, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [published online ahead of print December 20, 2010]. Circulation. 2011; 123(1):104-123. doi: 10.1161/CIR.0b013e31820f14c0
9. Olshansky B, Rosenfeld LE, Warner AL, et al. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol. 2004; 43(7):1201-1208. doi: 10.1016/j.jacc.2003.11.032 (Pubitemid 38452597)
10. Ahuja RC, Sinha N, Saran RK, Jain AK, Hasan M. Digoxin or verapamil or metoprolol for heart rate control in patients with mitral stenosis - a randomised cross-over study. Int J Cardiol. 1989; 25(3):325-331. doi: 10.1016/0167-5273(89)90223-4 (Pubitemid 19283585)
11. Lewis RV, McMurray J, McDevitt DG. Effects of atenolol, verapamil, and xamoterol on heart rate and exercise tolerance in digitalised patients with chronic atrial fibrillation. J Cardiovasc Pharmacol. 1989; 13(1):1-6. doi: 10.1097/00005344-198901000-00002 (Pubitemid 19032330)
12. Platia EV, Michelson EL, Porterfield JK, Das G. Esmolol versus verapamil in the acute treatment of atrial fibrillation or atrial flutter. Am J Cardiol. 1989; 63(13):925-929. doi: 10.1016/0002-9149(89)90141-0 (Pubitemid 19105127)
13. Tamariz LJ, Bass EB. Pharmacological rate control of atrial fibrillation. Cardiol Clin. 2004; 22(1):35-45. doi: 10.1016/S0733-8651(03)00111-5 (Pubitemid 38117301)
14. Segal JB, McNamara RL, Miller MR, et al. The evidence regarding the drugs used for ventricular rate control. J Fam Pract. 2000; 49(1):47-59. (Pubitemid 30489236)
15. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med. 1989; 321(6):406-412.
16. Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006; 114(7):e257-354. doi: 10.1161/CIRCULATIONAHA.106.177292
17. Khoo CW, Lip GY. Acute management of atrial fibrillation. Chest. 2009; 135(3):849-859. doi: 10.1378/chest.08-2183
18. Singh BN, Connolly SJ, Crijns HJ, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007; 357(10):987-999. doi: 10.1056/NEJMoa054686 (Pubitemid 47367078)
19. Køber L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008; 358(25):2678-2687. doi: 10.1056/NEJMoa0800456 (Pubitemid 351860860)
20. Brode S, Singh B, Anderson K. Sotalol. Card Electrophysiol Rev. 20. 1998; (2):211-214.
21. Singh S, Zoble RG, Yellen L, et al. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRED) study. Circulation. 2000; 102(19):2385-2390.
22. Pedersen OD, Bagger H, Keller N, Marchant B, Køber L, Torp-Pedersen C. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy. Circulation. 2001; 104(3):292-296. (Pubitemid 32666950)
23. Stambler BS. Ibutilide. Card Electrophysiol Rev.1998; (2):173-175. doi: 10.1023/A:1009967713885
24. Chiladakis JA, Kalogeropoulos A, Patsouras N, Manolis AS. Ibutilide added to propafenone for the conversion of atrial fibrillation and atrial flutter. J Am Coll Cardiol. 2004; 44(4):859-863. doi: 10.1016/j.jacc.2004.04.056 (Pubitemid 39099586)
25. Hennersdorf MG, Perings SM, Zühlke C, et al. Conversion of recent-onset atrial fibrillation or flutter with ibutilide after amiodarone has failed [published online ahead of print May 9, 2002]. Intensive Care Med. 2002; 28(7):925-929. doi: 10.1007/s00134-002-1317-3
26. Gopinathannair R, Olshansky B. Ibutilide revisited: stronger and safer than ever. Europace. 2009; 11(1):9-10. doi: 10.1093/europace/eun337
27. Volgman AS, Carberry PA, Stambler B, et al. Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation. J Am Coll Cardiol. 1998; 31(6):1414-1419. doi: 10.1016/S0735-1097(98)00078-3 (Pubitemid 28219138)
28. Simonian SM, Lotfipour S, Wall C, Langdorf MI. Challenging the superiority of amiodarone for rate control in Wolff-Parkinson-White and atrial fibrillation [published online ahead of print May 1, 2010]. Intern Emerg Med. 2010; 5(5):421-426. doi: 10.1007/s11739-010-0385-6
29. Wann LS, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Update on Dabigatran): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [published online ahead of print February 14, 2011]. Circulation. 2011; 123(10):1144-1150. doi: 10.1161/CIR.0b013e31820f14c0
30. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation [published online ahead of print August 30, 2009]. N Engl J Med. 2009; 361(12):1139-1151. doi: 10.1056/NEJMoa0905561